EGFR L858R Variants Tie Severe Acanthosis Nigricans to Pulmonary Disease
Early-onset generalized acanthosis nigricans is not always a metabolic clue. In three patients with normoglycemia, a striking pattern of periorificial hyperpigmentation, flexural thickening, and widespread skin disease pointed to something more unusual: activating EGFR variants with systemic consequences, including pulmonary nodules and lung disease.
The clinical picture matters because classic acanthosis nigricans usually raises concern for insulin resistance, obesity, or endocrine disease. Here, the phenotype appeared before any glucose abnormality and progressed beyond the skin. In that setting, the diagnosis should not stop at the surface. When thickened, velvety plaques appear in childhood or adolescence and extend to flexural sites, palms, soles, or the periorificial skin, a syndromic genetic disorder becomes a real possibility.
A Syndromic Pattern Across Skin, Hair, and Lung
The cohort included three individuals ages 8, 18, and 17 years, with two male patients and one female patient. Two had early-onset generalized skin disease with normoglycemia; one had first been labeled as having widespread epidermal nevus. Whole-exome sequencing identified the same EGFR L858R variant in all three participants. In generalized cases, the variant arose de novo; in the mosaic presentation, it was somatic.
The cutaneous phenotype extended beyond acanthosis nigricans alone. Generalized acquired keratoderma, flexural accentuation, woolly hair, and palmoplantar keratoderma formed part of the same syndrome. Pulmonary involvement completed the picture. Lung imaging showed nodules, and pulmonary function testing was part of the evaluation because the disease was not confined to the skin. For clinicians, this combination should trigger a broader diagnostic frame: a dermatologic sign may be the first visible marker of a cancer-associated signaling disorder.
EGFR Signaling Was Active in Affected Tissue
Lesional skin and cultured keratinocytes were not passive witnesses to the variant. They showed increased EGFR pathway activity, and that signaling could be suppressed pharmacologically in vitro. The biology is coherent. Activating EGFR variants can drive keratinocyte proliferation and epidermal hyperplasia, which fits the thickened, velvety, and hyperkeratotic skin changes seen in these patients. The same signaling axis also offers a plausible bridge to lung pathology, especially when nodules are present in a setting known to involve pulmonary cancer risk.
A skin eruption became a molecular disease.
That single shift changes the clinical task. Rather than treating the plaques as an isolated dermatologic nuisance, clinicians need to think about tissue-specific signaling, variant-driven disease, and whether the skin diagnosis is marking a deeper systemic process.
EGFR Inhibition Matched the Biology
Systemic treatment with EGFR inhibitors was associated with regression of skin disease. Pulmonary disease also improved, with resolution or reduction in the number of lung nodules. In a disorder driven by an activated receptor, that response is mechanistically sensible. Blockade of the abnormal signal should reduce the proliferative drive in both keratinocytes and affected pulmonary tissue, and the clinical course appears to follow that expectation.
This is not a routine acanthosis nigricans story. In common metabolic disease, the first step is usually to address insulin resistance and associated comorbidities. Here, the therapeutic target sits upstream of the phenotype itself. Recognizing the variant opens the door to pathogenesis-directed care, and the observed regression of both cutaneous and pulmonary manifestations suggests that the pathway is druggable in humans, not just in laboratory systems.
Pulmonary Nodules Raise the Stakes
Pulmonary nodules in this syndrome are more than incidental imaging findings. They matter because nodules can represent precursor lesions in a pathway connected to lung cancer risk, and the combination of generalized acanthosis nigricans with pulmonary disease shifts the urgency of diagnosis. A child or adolescent with diffuse flexural hyperpigmentation and keratoderma may need a workup that includes lung imaging, pulmonary assessment, and genetic testing rather than reassurance alone.
For dermatologists, pulmonologists, and clinical geneticists, the case series establishes a recognizable syndrome: acquired, generalized acanthosis nigricans with activating EGFR variants and systemic involvement. The skin findings are visible, but the clinical implications extend well beyond the skin exam. Early recognition may identify patients at risk for pulmonary disease while they are still candidates for targeted therapy.
Why This Case Series Changes Diagnostic Thinking
The most practical lesson is diagnostic, not cosmetic. Severe generalized acanthosis nigricans in a normoglycemic patient should prompt consideration of a molecular driver, especially when the distribution is atypical or accompanied by keratoderma, woolly hair, or lung abnormalities. Whole-exome sequencing proved decisive here, and the same strategy may help distinguish sporadic skin thickening from a heritable or de novo signaling disorder.
The series also sharpens the boundary between syndromic and nonsyndromic disease. Once an activating variant is identified, the skin lesion is no longer an isolated dermatologic endpoint. It becomes part of a broader phenotype that includes epidermal overgrowth and pulmonary involvement, with potential implications for surveillance and treatment selection.
Two clinical truths emerge from these patients. First, normoglycemia does not exclude serious disease when acanthosis nigricans is early, extensive, and progressive. Second, abnormal EGFR signaling can produce a treatable syndrome that crosses organ systems.
The remaining challenge is straightforward to state and difficult to solve: patients with this presentation still need timely recognition before pulmonary nodules and diffuse skin disease become entrenched. Broader awareness among dermatology, genetics, and pulmonary teams will determine how often this syndrome is found before it is mistaken for something far more common.